DANAHER CORP /DE/ News
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, municipal, industrial, and natural resource applications. It also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. The company was founded in 1969 and is headquartered in Washington, the District of Columbia.
see moreDANAHER CORP /DE/ Market News
6d
Danaher Appoints Julie Sawyer Montgomery as CEO Amid Masimo Integration and Q2 Strength
- Danaher (DHR) named Julie Sawyer Montgomery CEO effective October 1, 2026, as the company progresses Masimo integration following strong Q2 results.
29 Jul at 16:30
Danaher Corporation's Q2 2026 Earnings and Strategic Moves Amid Market Volatility
Danaher reports strong Q2 2026 earnings; stock faces market volatility.
26 Jul at 18:07
Danaher Corporation's Q2 2026 Earnings Report Triggers Significant Stock Decline
Danaher's Q2 2026 earnings report leads to a 15% stock drop amid investor concerns.
19 Jul at 18:04
Danaher Corporation's Strategic Acquisition of Masimo Corporation Enhances Diagnostics Portfolio
Danaher completes Masimo acquisition, strengthening diagnostics capabilities.
12 Jul at 18:02
Danaher Corporation's Strategic Moves Bolster Position in Life Sciences and Diagnostics
Danaher Corporation's recent acquisition of Masimo Corporation and financial performance highlight its strategic growth in the life sciences and diagnostics sectors.
07 Jul at 04:49
Danaher Corporation Completes Acquisition of Masimo Corporation
Danaher finalizes Masimo acquisition, enhancing diagnostics portfolio.
25 May at 04:30
Danaher Q1 Beat Bioprocessing Orders Ignite Upside
Danaher’s Q1 results and guidance raise confidence in a nascent bioprocessing upcycle. Strong orders, biotech sales growth and the nearing Masimo acquisition are tangible catalysts that offset diagnostic headwinds and strengthen DHR’s near-term earnings trajectory.